Inclusion completed

Cancer type Title Country
Bladder cancer A phase II single arm clinical trial of nivolumab (BMS936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent FI
Breast cancer A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer SE
Breast cancer A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to An-astrozole alone, in Post menopausal Women With Hormone Receptor positive, Endocrine T FI
Breast cancer A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation NO
Breast cancer First in human study in HER2 positive primary breast cancer patient who are eligible for neoadjuvant chemotherapy DK
Breast cancer Randomized phase II study of afatinib alone or in combination with vinorelbine versus investigator’s choice of treatment in patients with HER2-positive breast cancer with pro-gressive brain metastases after trastuzumab or lapatinib based therapy FI
Cholangiocarcinoma A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma DK
Colorectal cancer A double blinded randomised three armed phase II trial of PledOx in two different doses in combination with FOLFOX6 compared to placebo + FOLFOX6 in patients with advanced metastatic colorectal (stage IV) cancer SE
Colorectal cancer A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer NO
Colorectal cancer An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of Modufolin® in Combination with a Fixed Dose of 5-Fluorouracil (5-FU) alone or together with a Fixed Dose of Oxaliplatin or Irinotecan in Patients with Stage IV Colorectal Cancer NO
Colorectal cancer Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours DK
Colorectal cancer Open-label , single-arm, phase II study of bevacizumab (Avastin) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer FI
Gastric cancer Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunutinib. A Non-comparative phase II multicenter study study by the Scandinavian Sarcoma Group FI
Glioblastoma Electrochemotherapy as a Palliative Treatment for Brain Metastases DK
Head and Neck cancer ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group; EORTC protocol 1410-BTG/AbbVie protocol M14-483 FI
Head and Neck cancer An open-label, non-randomised, multicentre phase 1/2 trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed crizotinib treatment. SE
Leukemia A multicenter open randomised phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) DK
Leukemia A multicentre open randomized phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) DK
Leukemia A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q NO
Leukemia A randomized, open label, phase 2 study of the selective inhibitor of nuclear export (sine) selinexor (kpt-330) versus specified physician’s choice in patients ≥ 60 years old with relapsed/refractory acute myeloid leukemia (aml) who are ineligible for int DK
Leukemia A safety and efficacy study of adding low dose pegylated IFN-alpha 2b to standard dose dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia DK
Leukemia A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia NO
Lung cancer A phase I/IIa study of UV1 vaccination in patients with non-small cell lung cancer NO
Lung cancer A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer NO
Lung cancer IDO Peptide Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients DK
Lung cancer Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma NO
Lung cancer Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma NO
Lymphoma A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma DK
Lymphoma A Two Stage Phase Ib Study to Investigate the Pharmocokinetics and Tolerability of Rituximab Subcutaneous Formulation in Pats With Follicular Lymphoma as Part of Maintenance Treatement FI
Lymphoma Chemo-immunotherapy with early central nervous system (CNS) prophylaxis DK
Lymphoma Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk Diffuse Large B-Cell Lymphoma (NLG-LBC05) FI
Lymphoma Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine,vindesine, temozolomi-de and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomi FI
Lymphoma Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal AntibodyKW-0761(mogamulizumab) in Subjects with Previously Treated Peripheral T-Cell Lymphoma (PTCL) DK
Lymphoma Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY-80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin´s lymphomas FI
Lymphoma Randomised phase II trial on primary chemotherapy with high-dose methtrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cell trans DK
Lymphoma Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial FI
Lymphoma, Sarcoma Cross tumoral phase II clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET NO
Melanoma A randomised Phase II study of MK-3475 versus Chemotherapy in Pateients with Advanced Melanoma NO
Melanoma Safety and efficacy of intratumoural electrotransfer of Plasmid AMEP in patients suffering from advanced or metastatic melanoma: an open phase 1 trial DK
Melanoma Safety of UV1 vaccination in combination with ipilimumab in patients with unresectable or metastatic malignant melanoma NO
Melanoma T-cell therapy for patients with malignant melanoma DK
Melanoma The Melanoma Goup Trial: TOL + vemurafenib followed by interferon + vemurafenib maintenance (BRAF-positive patients) or TOL followed by interferon maintenance (BRAF-negative patients) FI
Melanoma Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma DK
Meningioma Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group NO
Multiple diagnosis A first-in-human, multicenter, open-label, multiple ascending dose Phase I study in patients with advanced solid tumors to determine the safety, pharmacokinetics and pharmacodynamics of intratumorally administered ADC-1013 SE
Multiple diagnosis, Solide tumores An Open-Label, Multicohort, Phase II study of Atezolizumab in Advanced Solid Tumors NO
Myeloma Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma DK
Ovarian cancer A phase II non comparative study with paclitaxel and carboplatin in combination with vorinostat in patients with advanced recurrent epithelia ovarian carcinoma DK
Pancreatic cancer A Phase I/II Trial and TG01 Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas NO
Pancreatic cancer Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer SE
Pancreatic cancer Safety, pharmacokinetics and efficacy of AXP107-11 in patients with standard gemcitabine (Gemzar®) treatment in patients with locally advanced or metastatic, unresectable, adenocarcinoma of the pancreas, stage III-IV. SE
Prostate cancer A phase I/IIa study of UV1 vaccination in patients with hormone-sensitive metastatic prostate cancer NO
Prostate cancer DC-005 Prostate NO
Prostate cancer Dendritic cell vaccination in combination with Docetaxel for patients with prostate cancer – a randomized phase II study DK
Prostate cancer Open, single-arm, multicenter, phase II trial investigating the safety of biweekly cabazi-taxel in metastatic castration resistant prostate cancer patients previously treated with docetaxel-containing regimen FI
Prostate cancer Safety and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer: open, non-randomised, uncontrolled, multicentre, multiple dose escalation study with randomised phase II expansion component FI
Prostate cancer Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (DUALIDES) FI
Sarcoma Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group NO
Solide tumores A phase 1, open label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function SE
Solide tumores A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced or Metastatic Solid Tumor Malignancies DK
Solide tumores A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on dovitinib (TKI258) pharmacokinetics in patients with advanced solid tumors DK
Solide tumores A phase I/II , open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors FI
Solide tumores An open-level, multicentre, dose-escalation, phase I study with an expansion phase, to evaluate safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic FI
Solide tumores MetAction: Actionable Target Identification for Palliative Systemic Therapy NO
Solide tumores Second generation Braf inhibitor (after lead compound vemurafenib) in Braf mutated solid tumors, and extension phase in melanomas and colorectal cancer DK